Trials / Terminated
TerminatedNCT00615784
Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
A Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the activity of bexarotene, a retinoic acid class drug, in patients with Acute Myeloid Leukemia (AML) that has returned after or is resistant to standard chemotherapy or are otherwise not eligible for conventional chemotherapy. Retinoic acids are a class of drugs related to Vitamin A, and have a wide range of effects within normal and malignant cells that affect cell growth and cell death.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bexarotene | Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient |
Timeline
- Start date
- 2010-05-25
- Primary completion
- 2013-10-01
- Completion
- 2013-11-08
- First posted
- 2008-02-14
- Last updated
- 2020-12-17
- Results posted
- 2020-11-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00615784. Inclusion in this directory is not an endorsement.